ArticlePDF Available

The Importance of Cardiovascular Research: What are we looking for?

Authors:
  • Alfred I. duPont Hospital for Children
Journal of Heart and
Cardiology
Editorial
Takeshi Tsuda*
Corresponding author: Associate Professor of Pediatrics,
Sidney Kimmel Medical College of Thomas Jefferson, Uni-
versity, and Philadelphia, PA 19107 Tel: (302)651-6677; Fax:
(302)651-6601; E-mail: ttsuda@nemours.org
Received Date: December 29, 2014
Accepted Date: December 30, 2014
Published Date: December 31, 2014
Citation: Tsuda, T. The importance of Cardiovascular Research: What
are we looking for? (2014) J Heart Cardiol 1(1): 1-2.
J Heart Cardiol | Volume 1: Issue 1
www.ommegaonline.com
Editorial
I used to naively and optimistically believe that the ad-
vance in medical science and technology would eventually solve
the majority of clinical problems. In the mid 80s when I was
a medical student in Japan, cancer disorders were perceived as
“progressive and lethal” by both physicians and patients. Treat-
ment strategy was still empiric and far from strategic and com-
prehensive. Without question, they were the biggest challenges
and threats to the entire society at that time. Thanks to marvelous
progress in integrated management with chemotherapy, surgical
intervention, and radiation therapy, etc., the modern medicine
has been able to conquer some types of cancers. Instead, howev-
er, we began to see increased number of heart failure in cancer
survivors secondary to specic cancer chemotherapy[1]. By solv-
ing one existing problem, we simply created another problem:
chemotherapy-induced-cardiomyopathy. Its pathogenesis and
effective treatment are still not fully understood. Although a
potent chemotherapy has signicantly improved survival and,
in part, quality of life, it is not always complication-free. Some
complications are just as bad as the original disease. With new
therapeutic modalities, we started to see a number of unexpected
new pathological conditions never experienced in the past.
Heart failure is a progressive lethal disease that has
signicant morbidity and mortality. Nearly 5.7 million people
suffer from heart failure in the United States alone (2008)[2], and
20% die within rst year after the diagnosis[3]. This is a signif-
icant social impact. According to the textbook of Colucci and
Braunwald (“Heart Disease”, 6th Ed, 2001, McGraw Hill), heart
failure is dened as “the pathological state or clinical syndrome
in which the heart is unable to pump blood commensurate with
the requirements of the metabolizing tissues or can do so only
with an elevated lling pressure.” Although the nal common
physiological outcome is the same, the underlying mechanisms
that cause heart failure are diverse and complex. The underly-
ing mechanisms of heart failure are poorly understood. Heart is
known as the most durable, integral, and indispensible organ to
maintain life. Besides the natural end of life, we have not yet elu-
cidated the underlying mechanisms of heart failure; nonetheless,
there must be strong factors at play that cause this diligent organ
to stop functioning. What are they? Why does myocardial tissue
fail to work properly? The understanding of molecular biology,
cell and matrix biology, and gene regulation is critical in answer-
ing these questions.
Heart failure is indeed a clinical syndrome involving
multiple organ systems. It is not merely a hemodynamic disabil-
ity of the heart as a pumping organ, but also represents loss of
regulation of the complex network communication among multi-
ple organs including heart, lungs, kidneys, liver, brain, gut, skel-
etal muscles, and endocrine organs, as all depend upon essential
supply provided by the heart. The disruption of these cross-talks
can be both the cause and/or result of failing circulation. What
are the methods in communicating with the distant organs? What
are the hormones that the heart can produce other than natri-
uretic peptides? The understanding of an endocrine role of the
heart is limited and needs to be further investigated[4]. Alteration
in immune system and dysregulated inammatory process are
heavily involved in the development of heart failure[5] and vas-
cular diseases[6]. To better understand the heart disease and the
patients with heart disease, it is imperative for all practicing car-
diologists to appreciate the importance of medical research, both
basic and clinical. Research is an unending human endeavor to
tackle unanswered questions we encounter for the patients and
for ourselves.
In the modern era, there are much more to learn than
what we used to learn in the past. As Hippocrates said, “Art is
long, life is short, opportunity eeting, experience treacherous,
judgment difcult”, there is so much to learn and so little to ac-
quire within a limited time. We sometimes lose ourselves in
the midst of the enormity, complexity and diversity of available
medical information. But this is who we are as medical profes-
sionals to be able to serve our patients. Any research experience
in the professional career would likely to help each individual
guide to make a sound judgment in the chaos. Investing your
time and effort in research activity does not pay off immediately,
but would certainly help you build up your future professional
strength when you encounter these problems.
The importance of Cardiovascular Research: What are we looking for?
Copy rights: ©2014 Tsuda, T. This is an Open access article distributed under the terms of Creative Commons Attribution 4.0
International License. 1
Cardiologist, Nemours Cardiac Center, Nemours/Alfred I. duPont Hospital for Children, 1600 Rockland Rd, Wilmington, DE, 19803, Philadel-
phia
Tsuda, T
2
References
1. Hahn, V.S., Lenihan, D.J., Ky, B. Cancer therapy-induced cardio-
toxicity: Basic mechanisms and potential cardioprotective therapies.
(2014) J American Heart Association 3: e000665.
2. Roger, V.L., Go, A.S., Lloyd-Jones, D.M., et al. Heart disease and
stroke statistics--2012 update: A report from the american heart associ-
ation. (2012) Circulation 125(1): 187-197.
3. Stewart, S., MacIntyre, K., Hole, D.J., et al. More “malignant” than
cancer? Five-year survival following a rst admission for heart failure.
(2001) Eur J Heart 3(3): 315-322.
4. Clerico, A., Recchia, F.A., Passino, C., et al. Cardiac endocrine func-
tion is an essential component of the homeostatic regulation network:
Physiological and clinical implications. (2006) Am J Physiol Heart Circ
Physiol 290(1): 17-29.
5. Van Linthout, S., Miteva, K., Tschope, C. Crosstalk between bro-
blasts and inammatory cells. (2014) Cardiovasc Res 102(2): 258-269
6. Schober, A. Chemokines in vascular dysfunction and remodeling.
Arteriosclerosis, thrombosis, and vascular biology. (2008) Arterioscler
Thromb Vasc Biol 28(11): 1950-1959.
J Heart Cardiol | Volume 1: Issue 1www.ommegaonline.com
ResearchGate has not been able to resolve any citations for this publication.
Article
Full-text available
T he patient is a 63-year-old man with a history of well-controlled hypertension who is diagnosed with diffuse large B-cell lymphoma and treated with a doxorubicin-containing chemotherapy regimen. During therapy, he is continued on hydrochlorothiazide for his hypertension. Three months later, he complains of dyspnea on exertion and mild lower extremity edema. A transthoracic echocardiogram reveals a moderately reduced left ventricular ejection fraction (LVEF), which is new compared with a study performed before he underwent chemotherapy.
Article
Full-text available
Fibroblasts, which are traditionally recognized as a quiescent cell responsible for extracellular matrix production, are more and more appreciated as an active key player of the immune system. This review describes how fibroblasts and immune cells reciprocally influence the pathogenesis of fibrosis. An overview is given how fibroblasts are triggered by components of the innate and adaptive immunity on the one hand and how fibroblasts modulate immune cell behaviour via conditioning the cellular and cytokine microenvironment on the other hand. Finally, latest insights into the role of cardiac fibroblasts in the orchestration of inflammatory cell infiltration in the heart, and their impact on heart failure, are outlined.
Article
Full-text available
The discovery of cardiac natriuretic hormones required a profound revision of the concept of heart function. The heart should no longer be considered only as a pump but rather as a multifunctional and interactive organ that is part of a complex network and active component of the integrated systems of the body. In this review, we first consider the cross-talk between endocrine and contractile function of the heart. Then, based on the existing literature, we propose the hypothesis that cardiac endocrine function is an essential component of the integrated systems of the body and thus plays a pivotal role in fluid, electrolyte, and hemodynamic homeostasis. We highlight those studies indicating how alterations in cardiac endocrine function can better explain the pathophysiology of cardiovascular diseases and, in particular of heart failure, in which several target organs develop a resistance to the biological action of cardiac natriuretic peptides. Finally, we emphasize the concept that a complete knowledge of the cardiac endocrine function and of its relation with other neurohormonal regulatory systems of the body is crucial to correctly interpret changes in circulating natriuretic hormones, especially the brain natriuretic peptide.
Article
Vascular remodeling stands for structural changes of the vessel wall in response to various noxious stimuli, which results in reorganization of the vessel wall architecture. Luminal narrowing because of neointima formation and constrictive remodeling leading to hypoperfusion is the most relevant clinical effect. Smooth muscle cell (SMC) accumulation, inflammatory cell recruitment, and endothelial regeneration are the critical parts in obstructive vascular remodeling. Chemokines and chemokine receptors have a great impact on initiating and progressing neointimal formation by controlling each step of the remodeling process. SDF-1alpha regulates vascular repair by CXCR4-dependent smooth muscle progenitor cell recruitment, which contributes to the maladaptive response to injury. The three distinct chemokine-chemokine receptor pairs MCP-1/CCR2, RANTES/CCR5, and Fractalkine/CX(3)CR1 direct lesional leukocyte infiltration. In addition MCP-1/CCR2 and Fractalkine/CX(3)CR1 increase neointimal SMC expansion. In contrast, KC/Gro-alpha supports endothelial recovery through CXCR2, which attenuates neointima formation. These findings highlight the importance to characterize specific functions of the chemokine network to enable therapeutic intervention.
Article
The prognostic impact of heart failure relative to that of 'high-profile' disease states such as cancer, within the whole population, is unknown. All patients with a first admission to any Scottish hospital in 1991 for heart failure, myocardial infarction or the four most common types of cancer specific to men and women were identified. Five-year survival rates and associated loss of expected life-years were then compared. In 1991, 16224 men had an initial hospitalisation for heart failure (n=3241), myocardial infarction (n=6932) or cancer of the lung, large bowel, prostate or bladder (n=6051). Similarly, 14842 women were admitted for heart failure (n=3606), myocardial infarction (n=4916), or cancer of the breast, lung, large bowel or ovary (n=6320). With the exception of lung cancer, heart failure was associated with the poorest 5-year survival rate (approximately 25% for both sexes). On an adjusted basis, heart failure was associated with worse long-term survival than bowel cancer in men (adjusted odds ratio, 0.89; 95% CI, 0.82-0.97; P<0.01) and breast cancer in women (odds ratio, 0.59; 95% CI, 0.55-0.64; P<0.001). The overall population rate of expected life-years lost due to heart failure in men was 6.7 years/1000 and for women 5.1 years/1000. With the notable exception of lung cancer, heart failure is as 'malignant' as many common types of cancer and is associated with a comparable number of expected life-years lost.
  • Thrombosis Arteriosclerosis
Arteriosclerosis, thrombosis, and vascular biology. (2008) Arterioscler Thromb Vasc Biol 28(11): 1950-1959.
  • Arteriosclerosis
Arteriosclerosis, thrombosis, and vascular biology. (2008) Arterioscler Thromb Vasc Biol 28(11): 1950-1959.